CD19 and cancer: Another valid study on haematological malignancies focused on bispecific CD19-CD22-CAR-T cells, which were shown to specifically target CD19+ and CD22+ human leukemic cells, generate interferon (IFN)-, and efficiently eradicate the target cancer cells in immune-deficient mice.